Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases

被引:15
|
作者
Eljarrah, Adam [1 ,2 ]
Gergues, Marina [1 ,2 ]
Pobiarzyn, Piotr W. [1 ,2 ]
Sandiford, Oleta A. [1 ,2 ]
Rameshwar, Pranela [3 ]
机构
[1] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA
[2] Univ Med & Dent New Jersey, Grad Sch, Rutgers Sch, Newark, NJ USA
[3] Rutgers Sch Biomed Hlth Sci, New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ 07107 USA
来源
关键词
Mesenchymal stem cells; Cytokines; Cell therapy; Drug delivery; Immune response; Graft-versus-host response; REGULATORY T-CELLS; MARROW STROMAL CELLS; VERSUS-HOST-DISEASE; B-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; DENDRITIC CELLS; MURINE MODEL; INHIBIT; PROLIFERATION; DIFFERENTIATION;
D O I
10.1007/978-3-030-31206-0_5
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Mesenchymal stem cells (MSCs) are multipotent cells that can self--renew and differentiate into cells of all germ layers. MSCs can be easily attracted to the site of tissue insult with high levels of inflammatory mediators. The general ability of MSCs to migrate at the sites of tissue injury suggested an innate ability for these cells to be involved in baseline tissue repair. The bone marrow is one of the primary sources of MSCs, though they can be ubiquitous. An attractive property of MSCs for clinical application is their ability to cross allogeneic barrier. However, alone, MSCs are not immune suppressive cells. Rather, they can be licensed by the tissue microenvironment to become immune suppressor cells. Immune suppressor functions of MSCs include those that blunt cytotoxicity of natural killer cells, suppression of T-cell proliferation, and "veto" function. MSCs, as third-party cells, suppress the immune response that generally recapitulates graft-versus-host disease (GvHD) responses. Based on the plastic functions of MSCs, these cells have dominated the field of cell-based therapies, such as anti-inflammatory and drug delivery. Here, we focus on the potential use of MSC for immunological disorders such as Crohn's disease and GvHD.
引用
收藏
页码:93 / 108
页数:16
相关论文
共 50 条
  • [41] IMMUNOTHERAPY OF IMMUNE-MEDIATED DISEASES
    PANAYI, GS
    KINGSLEY, GH
    LANCHBURY, JSS
    QUARTERLY JOURNAL OF MEDICINE, 1992, 83 (303): : 489 - 495
  • [42] IMMUNE-MEDIATED SKIN DISEASES
    ROSSER, EJ
    VETERINARY QUARTERLY, 1995, 17 : S37 - S38
  • [43] IMMUNE-MEDIATED DISEASES OF THE BLOOD
    DODDS, WJ
    ADVANCES IN VETERINARY SCIENCE AND COMPARATIVE MEDICINE, 1983, 27 : 163 - 196
  • [44] Osteopontin in Immune-mediated Diseases
    Rittling, S. R.
    Singh, R.
    JOURNAL OF DENTAL RESEARCH, 2015, 94 (12) : 1638 - 1645
  • [45] Treating immune-mediated diseases
    Léger, JM
    PRESSE MEDICALE, 2006, 35 (04): : 707 - 708
  • [46] Apoptosis in immune-mediated diseases
    Sankari, S. Leena
    Babu, N. Aravindha
    Rajesh, E.
    Kasthuri, M.
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2015, 7 (05): : S200 - S202
  • [47] Immune-mediated liver diseases
    Strassburg, C. P.
    Trautwein, C.
    GASTROENTEROLOGE, 2018, 13 (03): : 170 - 170
  • [48] The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
    Anchang, Charles Gwellem
    Xu, Cong
    Raimondo, Maria Gabriella
    Atreya, Raja
    Maier, Andreas
    Schett, Georg
    Zaburdaev, Vasily
    Rauber, Simon
    Ramming, Andreas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)
  • [49] Therapeutic Potential of Fetal Mesenchymal Stem Cells
    Roubelakis, Maria G.
    CURRENT STEM CELL RESEARCH & THERAPY, 2013, 8 (02) : 115 - 116
  • [50] Therapeutic Potential of Mesenchymal Stem Cells in PCOS
    Nejabati, Hamid Reza
    Nikzad, Sadeneh
    Roshangar, Leila
    CURRENT STEM CELL RESEARCH & THERAPY, 2024, 19 (02) : 134 - 144